Day: February 24, 2022

MOUNT HOREB, Wis., Feb. 24, 2022 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s casual wear, workwear and accessories, today announced that it will report fourth quarter 2021 financial results before market on Thursday, March 10. 2022. A conference call and audio webcast with analysts and investors will be held on Thursday, March 10, 2022 at 9:30 am Eastern Time, to discuss the results and answer questions. Live conference call: 844-875-6915 (domestic) or 412-317-6711 (international)Conference call replay available through March 17, 2022: 877-344-7529 (domestic) or 412-317-0088 (international)Replay access code: 9177748 Live and archived webcast: ir.duluthtrading.com To expedite entry into the call and avoid waiting for a live operator,...

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments. To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 5058194. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint...

– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting – – Pre-clinical Data on CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted for Presentation at the AACR Annual Meeting – – CFT8634 Phase 1/2 Clinical Trial in Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors Expected to Initiate in 1H 2022; CFT1946 IND Application Submission and Phase 1 Trial Initiation Expected in 2H 2022 – – Year-end Cash, Cash Equivalents and Marketable Securities Expected to Provide Runway to End of 2024 – WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, Ontario, Feb. 24, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In consultation with the CEO, CFO, and COO, Microbix’s Board of Directors has approved the issuance of 2,805,000 options in accordance with the terms of the Stock Option Plan. These approved options are exercisable at a price of $0.60 per share, as determined by the closing price of the TSX on 18 February, 2022. Each option will vest and be exercisable after...

CALGARY, Alberta, Feb. 24, 2022 (GLOBE NEWSWIRE) — CE Brands Inc. (TSXV: CEBI; CEBI.WT) (“CE Brands”, “we”, “our”, or the “Company”), a data-driven consumer-electronics company, today announced its financial results for the three-month and nine-month periods ended December 31, 2021 (“Q3 2022”) ⁽¹⁾. The related condensed interim consolidated financial statements and Management’s Discussion and Analysis for Q3 2022 are available on SEDAR at www.sedar.com and on CE Brands’ website at www.cebrands.ca. Q3 2022 HighlightsTotal Revenue in Q3 2022 was $1.5 million representing the third consecutive quarter of increasing revenue (Q2 2022 – $1.4 million and Q1 2022 – $1.1 million). The quarter over quarter increases in revenue from Q2 2022 were primarily a result of increased sales of baby monitors and initial sales of the...

Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor, ZN-c3, for the treatment of uterine serous carcinoma (USC) Initiated two additional trials with ZN-c3, including a potentially registrational biomarker-driven Phase 2 trial and a Phase 1/2 trial in combination with GSK’s PARP inhibitor, niraparib, in ovarian cancer Announced the addition of a preclinical BCL-xL heterobifunctional degrader candidate to its pipeline Ended year with $339.9 million in cash, cash equivalents and short-term investments NEW YORK and SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage”) (CSE:ACRG.A.U, ACRG.B.U), (OTCQX: ACRHF, ACRDF), a vertically integrated, multi-state operator of cannabis cultivation and retailing facilities in the U.S., today announced it will report its fourth quarter and full year 2021 financial results for the period ending December 31, 2021, on March 10, 2022, after market close. Management will host a conference call on March 11, 2022, at 10:00 a.m. ET to discuss the results in detail. Conference call details:Date: Friday, March 11, 2022Time: 10:00 a.m. ETWebcast: Click hereDial-in: Canada – (833) 950-0062 (toll-free) or (226) 828-7575 (local)  US – (844) 200-6205 (toll-free) or (646) 904-5544 (local)Conference ID: 129591The webcast will be archived and can be accessed via Acreage’s...

– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder – – First Patients Dosed in All Three Pivotal Trials of PYRUKYND® in Thalassemia and Sickle Cell Disease – – Cash, Cash Equivalents and Marketable Securities $1.3 Billion as of Dec. 31; Expects Strong Cash Position to Enable Execution of Robust Operating Plan to Cash-Flow Positivity – CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2021. “With last week’s FDA approval of PYRUKYND® for the treatment...

NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company’s financial results and to provide a general business update.Conference Call & Webcast Details   Date/Time: Thursday, March 10, 2022 at 8:30 AM Eastern TimeDomestic: 877-407-5795International: 201-689-8722The webcast and the accompanying materials will be accessible* under...

EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer will participate in the “Infectious Disease” panel at the Cowen 42nd Annual Health Care Conference, which is being held virtually from March 7 to 9. Panel DetailsTitle: Infectious DiseaseDate and Time: Wednesday, March 9th from 10:30 – 11:30 a.m. ET A live webcast of the panel will be accessible via the Investors & Media section of the company’s website at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event. About Gritstone bioGritstone bio, Inc. (Nasdaq: GRTS),...